PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION

DOI: https://doi.org/10.29296/25877305-2020-02-15
Download full text PDF
Issue: 
2
Year: 
2020

Professor V. Isakov, Dr Med. Sci. Pavlov First Saint Petersburg State Medical University Health Centre for Herpesvirus Infections and Immune Rehabilitation, part of Sokolov Clinical Hospital No. 122

Influenza and other respiratory viruses cause imbalance in the interferon system, and suppression of cellular and phagocytic reactions in vivo. Prolonged persistence of viral and bacterial pathogens affects the atopy development and can lead to exacerbations of chronic respiratory tract diseases. Today the world is concerned with the ongoing epidemic in China caused by a novel RNA virus COVID-2019 (COrona VIrus Disease 2019). This paper presents information about the origin, spread and clinical symptoms of coronavirus infection. Prevention and treatment options for various coronavirus diseases, that can also be helpful in case of COVID-2019, are discussed.
Keywords: 
инфекционные болезни
коронавирусная инфекция
коронавирус COVID-2019
пневмония
профилактика
интерфероны
Гриппферон

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Krasnov V.V. Effektivnost' rekombinantnogo interferona-al'fa v lechenii i profilaktike ORVI // Vopr. prakt. pediatr. – 2016; 11 (4): 44–52 [Krasnov V.V. The efficacy of recombinant interferon-alpha in the treatment and prevention of ARVI // Vopr. prakt. pediatr. = Clinical Practice in Pediatrics. – 2016; 11 (4): 44–52 (in Russ.)]. DOI: 10.20953/1817-7646-2016-4-44-5
  2. Derjabin P.G., Zarubaeva V.V. K voprosu o koronavirusnoj infektsii i perspektivah profilaktiki i lechenija preparatami interferona al'fa-2b chelovecheskogo rekombinantnogo // Infektsionnye bolezni. – 2014; 3: 32–4 [Deryabin P.G., Zarubaev V.V. Regarding the Coronavirus infection and prospects for prevention and treatment by recombinant human interferon alpha-2b medications // Infektsionnye bolezni. – 2014; 3: 32–4 (in Russ.)].
  3. Issledovanie po otsenke protivovirusnoj aktivnosti preparata Grippferon® v otnoshenii koronavirusov, vyzyvajuschih Tjazhelyj Ostryj Respiratornyj sindrom (SARS) i Blizhnevostochnyj respiratornyj sindrom (MERS) [Issledovanie po otsenke protivovirusnoi aktivnosti preparata Grippferon® v otnoshenii koronavirusov, vyzyvayushchikh Tyazhelyi Ostryi Respiratornyi sindrom (SARS) i Blizhnevostochnyi respiratornyi sindrom (MERS) (in Russ.)] URL: https://www.firnm.ru/2020/01/3536-grippferon-assessment-of-antiviral-activity-against-sars-and-mers-coronaviruses/
  4. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) // Biosci. Trends. – 2020 Jan 28. DOI: 10.5582/bst.2020.01020
  5. Sheahan T., Sims A., Leist S. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV // Nat. Commun. – 2020; 11 (1): 222. DOI: 10.1038/s41467-019-13940-6